What is Silo Pharma Inc's earnings per share (EPS)?

Silo Pharma Inc (SILO) reported diluted earnings per share of $-0.50 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Silo Pharma Inc Financials

SILO

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows Silo Pharma Inc (SILO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

1.10x

For every $1 of reported earnings, Silo Pharma Inc generates $1.10 in operating cash flow (-$4.7M OCF vs -$4.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-114.8x

Silo Pharma Inc earns $-114.8 in operating income for every $1 of interest expense (-$4.3M vs $37K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$72K

YoY+0.0%

5Y CAGR+12.0%

Silo Pharma Inc generated $72K in revenue in fiscal year 2025. This represents an increase of 0.0% from the prior year.

EBITDA

N/A

Net Income

-$4.2M

YoY+3.8%

Silo Pharma Inc reported -$4.2M in net income in fiscal year 2025. This represents an increase of 3.8% from the prior year.

EPS (Diluted)

$-0.50

Silo Pharma Inc earned $-0.50 per diluted share (EPS) in fiscal year 2025. This represents an increase of 58.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

$0.85

Silo Pharma Inc paid $0.85 per share in dividends in fiscal year 2025.

Shares Outstanding

14M

Silo Pharma Inc had 14M shares outstanding in fiscal year 2025. This represents an increase of 215.9% from the prior year.

Margins & Returns

Gross Margin

38.6%

YoY-53.3pp

5Y CAGR+368.9pp

Silo Pharma Inc's gross margin was 38.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 53.3 percentage points from the prior year.

Operating Margin

-5936.9%

YoY+589.5pp

5Y CAGR-556.8pp

Silo Pharma Inc's operating margin was -5936.9% in fiscal year 2025, reflecting core business profitability. This is up 589.5 percentage points from the prior year.

Net Margin

-5863.5%

YoY+229.1pp

5Y CAGR+1559.0pp

Silo Pharma Inc's net profit margin was -5863.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 229.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$2.2M

YoY-8.8%

5Y CAGR+141.6%

Silo Pharma Inc invested $2.2M in research and development in fiscal year 2025. This represents a decrease of 8.8% from the prior year.

Share Buybacks

$1.0M

Silo Pharma Inc spent $1.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

SILO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$72K0.0%	$72K0.0%	$72K0.0%	$72K+5858.8%	$1K-97.0%	$41K
Cost of Revenue	$44K+658.7%	$6K0.0%	$6K0.0%	$6K+16.7%	$5K-97.2%	$176K
Gross Profit	$28K-58.0%	$66K0.0%	$66K0.0%	$66K+1846.5%	-$4K+97.2%	-$135K
R&D Expenses	$2.2M-8.8%	$2.4M+180.2%	$845K-34.3%	$1.3M+85.4%	$694K+2543.5%	$26K
SG&A Expenses	N/A	N/A	$390K+71.6%	$227K+39.5%	$163K+224.7%	$50K
Operating Income	-$4.3M+9.0%	-$4.7M-22.0%	-$3.9M-6.3%	-$3.6M-32.2%	-$2.7M-24.6%	-$2.2M
Interest Expense	$37K+633.7%	$5K+4.4%	$5K+121.4%	$2K-27.6%	$3K+3695.0%	$80
Income Tax	N/A	N/A	N/A	N/A	$25K	N/A
Net Income	-$4.2M+3.8%	-$4.4M-18.7%	-$3.7M+5.3%	-$3.9M-200.1%	$3.9M+228.5%	-$3.0M
EPS (Diluted)	$-0.50	$-1.19+0.8%	$-1.20+29.8%	$-1.71-4375.0%	$0.04+180.0%	$-0.05

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K0.0%	$18K
Cost of Revenue	$21K+1317.9%	$1K-0.1%	$1K0.0%	$1K+0.1%	$1K0.0%	$1K-0.1%	$1K0.0%	$1K
Gross Profit	-$3K-116.1%	$17K0.0%	$17K0.0%	$17K0.0%	$17K0.0%	$17K0.0%	$17K0.0%	$17K
R&D Expenses	$544K-24.2%	$717K+20.8%	$594K-47.9%	$1.1M+120.2%	$518K+31.8%	$393K+23.4%	$318K-5.6%	$337K
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	$51K-21.4%	$64K	N/A
Operating Income	-$1.2M+7.8%	-$1.2M-14.1%	-$1.1M+39.7%	-$1.8M-79.5%	-$1.0M-0.7%	-$1.0M-14.0%	-$880K+24.4%	-$1.2M
Interest Expense	$886-46.2%	$2K-20.2%	$2K+654.0%	$274-74.7%	$1K-41.9%	$2K-0.6%	$2K+585.0%	$273
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.1M+7.8%	-$1.2M-16.8%	-$1.0M+40.4%	-$1.7M-86.3%	-$929K+0.3%	-$932K-16.2%	-$802K+28.5%	-$1.1M
EPS (Diluted)	$-0.12+36.8%	$-0.19+17.4%	$-0.23	N/A	$-0.22+29.0%	$-0.31-10.7%	$-0.28	N/A

SILO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$7.4M-4.3%	$7.7M-33.5%	$11.6M+11.0%	$10.5M+635.3%	$1.4M
Current Assets	N/A	$7.1M-7.4%	$7.7M-33.6%	$11.6M+11.2%	$10.4M+629.1%	$1.4M
Cash & Equivalents	N/A	$3.9M+10.8%	$3.5M-69.0%	$11.4M+15.6%	$9.8M+771.8%	$1.1M
Inventory	N/A	N/A	N/A	N/A	N/A	$33K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$2.4M+51.5%	$1.6M+20.5%	$1.3M-8.8%	$1.4M+878.2%	$146K
Current Liabilities	N/A	$1.7M+113.5%	$776K+77.8%	$436K-11.0%	$490K+245.8%	$142K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$5.0M-18.5%	$6.2M-40.3%	$10.3M+14.1%	$9.1M+607.6%	$1.3M
Retained Earnings	N/A	-$15.3M-40.4%	-$10.9M-51.6%	-$7.2M-119.8%	-$3.3M+43.4%	-$5.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$6.4M-4.0%	$6.7M+12.8%	$5.9M-20.4%	$7.4M-13.5%	$8.6M+6.6%	$8.0M+15.8%	$6.9M-10.4%	$7.7M
Current Assets	$6.2M-3.3%	$6.4M+13.7%	$5.6M-21.2%	$7.1M-13.9%	$8.3M+6.9%	$7.7M+12.4%	$6.9M-10.5%	$7.7M
Cash & Equivalents	$3.9M-9.6%	$4.3M+38.2%	$3.1M-19.7%	$3.9M-19.6%	$4.9M+7.9%	$4.5M+68.9%	$2.7M-24.3%	$3.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-20.7%	$1.7M-8.1%	$1.9M-20.6%	$2.4M+33.2%	$1.8M-14.2%	$2.1M+26.1%	$1.6M+5.1%	$1.6M
Current Liabilities	$708K-32.5%	$1.0M-11.4%	$1.2M-28.4%	$1.7M+58.5%	$1.0M-21.0%	$1.3M+51.4%	$874K+12.6%	$776K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.0M+1.9%	$4.9M+22.6%	$4.0M-20.3%	$5.0M-25.8%	$6.8M+13.8%	$6.0M+12.6%	$5.3M-14.3%	$6.2M
Retained Earnings	-$18.6M-6.3%	-$17.5M-7.4%	-$16.3M-6.8%	-$15.3M-12.8%	-$13.5M-7.4%	-$12.6M-8.0%	-$11.7M-7.4%	-$10.9M

SILO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.7M-21.6%	-$3.8M-18.9%	-$3.2M+7.8%	-$3.5M-53.5%	-$2.3M-96.9%	-$1.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$644K-33.9%	$974K+123.5%	-$4.1M-4882.9%	$87K-98.8%	$7.2M+18342.4%	$39K
Financing Cash Flow	$4.9M+49.9%	$3.2M+788.1%	-$471K-109.5%	$4.9M+30.2%	$3.8M+77.7%	$2.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$1.0M	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$955K+25.7%	-$1.3M+21.6%	-$1.6M-78.8%	-$917K+31.9%	-$1.3M-84.0%	-$732K+12.7%	-$838K+7.9%	-$910K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$95K-124.6%	$388K-55.5%	$871K+2413.9%	-$38K+6.9%	-$40K-104.2%	$954K+877.8%	$98K-97.8%	$4.4M
Financing Cash Flow	$635K	N/A	N/A	$0-100.0%	$1.7M+7.8%	$1.6M+1499.3%	-$115K+40.6%	-$194K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SILO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	38.6%-53.3pp	91.9%0.0pp	91.9%0.0pp	91.9%+405.4pp	-313.6%+16.8pp	-330.4%
Operating Margin	-5936.9%+589.5pp	-6526.4%-1179.0pp	-5347.4%-316.1pp	-5031.3%+221773.9pp	-226805.2%-221425.1pp	-5380.1%
Net Margin	-5863.5%+229.1pp	-6092.6%-960.0pp	-5132.6%+288.3pp	-5420.9%-328044.1pp	322623.2%+330045.7pp	-7422.5%
Return on Equity	N/A	-87.3%-27.4pp	-59.9%-22.1pp	-37.8%-80.9pp	43.1%+280.3pp	-237.2%
Return on Assets	N/A	-59.3%-11.5pp	-47.8%-14.2pp	-33.6%-70.8pp	37.2%+250.1pp	-212.9%
Current Ratio	N/A	4.29-5.6	9.90-16.6	26.52+5.3	21.23+11.2	10.07
Debt-to-Equity	N/A	0.47+0.2	0.25+0.1	0.13-0.0	0.16+0.0	0.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	-14.8%-106.7pp	91.9%0.0pp	91.9%0.0pp	91.9%0.0pp	91.9%0.0pp	91.9%0.0pp	91.9%0.0pp	91.9%
Operating Margin	-6388.2%+538.6pp	-6926.8%-857.1pp	-6069.7%+3990.0pp	-10059.7%-4456.0pp	-5603.6%-40.4pp	-5563.2%-684.1pp	-4879.1%+1576.7pp	-6455.8%
Net Margin	-6160.5%+520.7pp	-6681.2%-959.3pp	-5721.9%+3878.8pp	-9600.7%-4447.8pp	-5152.9%+16.4pp	-5169.4%-722.1pp	-4447.3%+1772.5pp	-6219.8%
Return on Equity	-22.2%+2.3pp	-24.5%+1.2pp	-25.7%+8.7pp	-34.4%-20.7pp	-13.7%+2.0pp	-15.6%-0.5pp	-15.2%+3.0pp	-18.1%
Return on Assets	-17.4%+0.7pp	-18.1%-0.6pp	-17.5%+5.9pp	-23.4%-12.5pp	-10.8%+0.8pp	-11.6%-0.0pp	-11.6%+2.9pp	-14.5%
Current Ratio	8.70+2.6	6.07+1.3	4.73+0.4	4.29-3.6	7.91+2.1	5.84-2.0	7.87-2.0	9.90
Debt-to-Equity	0.27-0.1	0.35-0.1	0.470.0	0.47+0.2	0.26-0.1	0.35+0.0	0.31+0.1	0.25
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Artelo Biosciences Inc ARTL

$5.2M

Pharmacyte Biotech Inc PMCB

$7.4M

CERo Therapeutics CERO

$177K

Ensysce Biosciences Inc ENSC

$2.2M

Polyrizon Ltd PLRZ

$19.6M

Frequently Asked Questions

What is Silo Pharma Inc's annual revenue?

Silo Pharma Inc (SILO) reported $72K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Silo Pharma Inc's revenue growing?

Silo Pharma Inc (SILO) revenue grew by 0% year-over-year, from $72K to $72K in fiscal year 2025.

Is Silo Pharma Inc profitable?

No, Silo Pharma Inc (SILO) reported a net income of -$4.2M in fiscal year 2025, with a net profit margin of -5863.5%.

What is Silo Pharma Inc's gross margin?

Silo Pharma Inc (SILO) had a gross margin of 38.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Silo Pharma Inc's operating margin?

Silo Pharma Inc (SILO) had an operating margin of -5936.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Silo Pharma Inc's net profit margin?

Silo Pharma Inc (SILO) had a net profit margin of -5863.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Silo Pharma Inc pay dividends?

Yes, Silo Pharma Inc (SILO) paid $0.85 per share in dividends during fiscal year 2025.

What is Silo Pharma Inc's operating cash flow?

Silo Pharma Inc (SILO) generated -$4.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Silo Pharma Inc spend on research and development?

Silo Pharma Inc (SILO) invested $2.2M in research and development during fiscal year 2025.

Does Silo Pharma Inc buy back shares?

Yes, Silo Pharma Inc (SILO) spent $1.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Silo Pharma Inc have outstanding?

Silo Pharma Inc (SILO) had 14M shares outstanding as of fiscal year 2025.

Are Silo Pharma Inc's earnings high quality?

Silo Pharma Inc (SILO) has an earnings quality ratio of 1.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Silo Pharma Inc cover its interest payments?

Silo Pharma Inc (SILO) has an interest coverage ratio of -114.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.